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Abstract 
 
       The anti-diabetic and hypoglycemic effects of P.ansium, which is used 
traditionally world wide for the treatment of several disease were studied.  The 
effect of the plant on the plasma glucose, total protein, albumin, bilrubin,  
cholesterol, triglyceride ,enzyme (GOT, GPT and alkaline phosphatase) and 
concentrations of N+ and K+ were evaluated in diabetic and normal rats. 
Adult male Wister albino rats were used in the present work. The diabetes was 
induced by injection of streptozotocin. The experiment extended over three 
weeks .Rats were divided into four groups each group consisted of 6 rats : 
Group A was control group and contained normal rats , fed rat diet only 
(63g/day), Group B contained normal rats fed P.anisum powder which replaced 
15% of diet  to examine the P.anisum effects on normal rats, Group C contained 
diabetic induced rats fed diet only (63g/day) and  Group D contained diabetic 
induced rats fed P.anisum powder which replaced 15% of rat's diet to examine 
the effects of feeding P.anisum on diabetic rats.      
The addition of 15% of P.anisum to the diet lowered significantly the plasma 
glucose level of diabetic rats at 0,1,2,3 h after overnight fasting when compared 
with diabetic fed diet only. 
The feeding of   P.anisum to normal rats, lowered the glucose level at 2h and 
elevated it significantly at 3h but the difference was small. 
The feeding P.anisum had no significant effect on plasma total protein, 
albumin, GOT, GPT , alkaline phosphatase , cholesterol , triglyceride, bilrubin,  
N+ and K+ concentrations in both normal and diabetic rats .Thus it could be 
concluded that P.anisum is unlikely to be toxic. 
It was noticed in this study, that the induction of diabetes in rats by 
 ix
streptozotocin caused significant elevation of plasma glucose level ,cholesterol 
and urea ; and lowered significantly plasma albumin , triglycerides and the body 
weight but the induced diabetes had no significant effect in plasma total protein 
,GOT,GPT, alkaline phosphatase, bilrubin creatinine , Na+ or K+ 
Therefore ,it can be concluded  P.anisum is promising antidiabetic agent and 
could be used to lower hyperglycemia in diabetic patient. 
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  ﻣﻠﺨﺺ اﻷﻃﺮوﺣﺔ
 اﻟﻤﻌﺎﻟﺞ اﻷﺛﺮ و اﻟﺪم ﻓﻲ اﻟﺠﻠﻮآﻮز  ﺘﺮآﻴﺰﻟ اﻟﺨﺎﻓﺾ اﻷﺛﺮ دراﺳﺔ ﺗﻢ اﻷﻃﺮوﺣﺔ هﺬﻩ ﻓﻲ
 آﺜﻴﺮ ﻟﻌﻼج  ﻟﻢاﻟﻌﺎ دول ﻣﻦ آﺒﻴﺮ ﻋﺪد ﻓﻲ ﻳﺴﺘﺨﺪم واﻟﺬي اﻟﻴﻨﺴﻮن ﻧﺒﺎت  ﻟﻤﺮض اﻟﺴﻜﺮي ﺑﻮاﺳﻄﺔ       
 ,اﻟﺒﻠﻴﺮوﺑﻦ,اﻻﻟﺒﻴﻮﻣﻴﻦ, اﻟﻜﻠﻰ اﻟﺒﺮوﺗﻴﻦ ,اﻟﺠﻠﻮآﻮز ﻧﺴﺒﺔ ﻋﻠﻲ ﺗﺄﺛﻴﺮﻩ ﺑﻤﺮاﻗﺒﺔ ذﻟﻚ و   اﻷﻣﺮاض ﻣﻦ
 ﻟﻠﻔﺌﺮان اﻟﺪم ﺑﻼزﻣﺎ ﻓﻲ  اﻟﺼﻮدﻳﻮم و اﻟﺒﻮﺗﺎﺳﻴﻮم , اﻷﻧﺰﻳﻤﺎت ﺑﻌﺾ و,  اتﻳﺪاﻟﺘﺮاﻳﺠﻠﻴﺴﺮ , اﻟﻜﻮﻟﺴﺘﺮول
 .  ﺳﻠﻴﻤﺔ أﺧﺮى و اﻟﺴﻜﺮي ﺑﻤﺮض ﻣﺼﺎﺑﺔ
 ﻋﻦ ﻣﻨﻬﺎ ﺟﺰء إﻣﺮاض ﺗﻢ اﻟﺘﻲ و اﻟﺒﻴﻀﺎء وﺳﺘﺮ ﻓﺌﺮان ﻣﻦ اﻟﺬآﻮر ﻋﻠﻰ  ﺒﺤﺚاﻟ هﺬا ﻓﻲ اﻟﺘﺠﺎرب أﺟﺮﻳﺖ
 ﻗﺴﻤﺖ و ﻣﺘﺼﻠﺔ أﺳﺎﺑﻴﻊ ﺛﻼﺛﺔ ﻟﻤﺪة  اﻟﺘﺠﺮﺑﺔ واﺳﺘﻤﺮت اﻻﺳﺘﺮﺑﺘﻮزﻳﺘﻮﺳﻦ ﻣﺎدة ﺑﻮاﺳﻄﺔ ﺣﻘﻨﻬﺎ ﻃﺮﻳﻖ
 و ﺿﺒﻂ ﻣﺠﻤﻮﻋﺔ اﻷوﻟﻰ اﻟﻤﺠﻤﻮﻋﺔ .ﻓﺌﺮان 6 ﻣﻦ ﺗﺘﻜﻮن ﻣﺠﻤﻮﻋﺔ آﻞ ﻣﺠﻤﻮﻋﺎت أرﺑﻊ إﻟﻰ اﻟﻔﺌﺮان
  ﺋﻬﺎﻏﺬا ﻣﻦ %51 اﺳﺘﺒﺪال ﺗﻢ  اﻟﺘﻲ و اﻟﺴﻠﻴﻤﺔ اﻟﻔﺌﺮان ﻣﻦ اﻟﺜﺎﻧﻴﺔ اﻟﻤﺠﻤﻮﻋﺔ  ,   ﺔاﻟﺴﻠﻴﻤ  ﺮانﻔﺌﻟﻠ  ﻣﺮاﻗﺒﺔ
 اﻟﺜﺎﻟﺜﺔ اﻟﻤﺠﻤﻮﻋﺔ ,  اﻟﺴﻠﻴﻤﻪ اﻟﻔﺌﺮان ﻓﻲ أﺛﺮﻩ ﻻﺧﺘﺒﺎر ذﻟﻚ و اﻟﻴﻨﺴﻮن ﺣﺒﻮب ﺑﻤﺴﺤﻮق )ﺟﺮام63( اﻟﻴﻮﻣﻲ
  ﺎأﻣ اﻻﺳﺘﺮﺑﺘﻮزﻳﺘﻮﺳﻦ ﻣﺎدة ﺑﻮاﺳﻄﺔ اﻟﺴﻜﺮى ﺑﺪاء أﻣﺮاﺿﻬﺎ ﺗﻢ اﻟﺘﻲ  ﺮانﻔﺌﻟﻠ  ﻣﺮاﻗﺒﺔ و ﺿﺒﻂ ﻣﺠﻤﻮﻋﺔ
 )ﺟﺮام63(  ﺮانﻔﺌﻟﻠ اﻟﻴﻮﻣﻲ اﻟﻐﺬاء ﻣﻦ %51 اﺳﺘﺒﺪال ﺗﻢ أﻳﻀﺎ أﻣﺮاﺿﻬﺎ ﺗﻢ اﻟﺘﻲ و اﻟﺮاﺑﻌﺔ اﻟﻤﺠﻤﻮﻋﺔ
     اﻟﺴﻜﺮي ﺑﻤﺮض  ﻤﺼﺎﺑﺔاﻟ  ﺮانﻔﺌﻟا ﻓﻲ أﺛﺮﻩ ﻻﺧﺘﺒﺎر  اﻟﻴﻨﺴﻮن ﺣﺒﻮب ﺑﻤﺴﺤﻮق
 
 اﻟﺪم ﺑﻼزم ﻓﻲ اﻟﺠﻠﻮآﻮز ﻣﺴﺘﻮى اﻧﺨﻔﺎض إﻟﻰ أدى ﺑﺎﻟﻴﻨﺴﻮن ﻟﻠﻔﺌﺮان اﻟﻴﻮﻣﻲ اﻟﻐﺬاء ﻣﻦ  %51 اﺳﺘﺒﺪال
 ﻓﻲ أﻣﺎ, اﻟﻴﻨﺴﻮن إﻋﻄﺎﺋﻬﺎ ﻳﺘﻢ ﻟﻢ واﻟﺘﻲ اﻟﻤﺼﺎﺑﺔ ﺑﺎﻟﻔﺌﺮان ﻣﻘﺎرﻧﺔ 3و2 ,0,1,اﻟﺴﺎﻋﺎت ﻓﻲ اﻟﻤﺼﺎﺑﺔ  ﺮانﻟﻠﻔﺌ
 ﻓﻲ ﻗﻠﻴﻞ ارﺗﻔﺎع و اﻟﺜﺎﻧﻴﺔ اﻟﺴﺎﻋﺔ ﻓﻲ اﻟﺠﻠﻮآﻮز ﻣﺴﺘﻮى اﻧﺨﻔﺎض إﻟﻰ اﻟﻴﻨﺴﻮن أدى اﻟﺴﻠﻴﻤﺔ اﻟﻔﺌﺮان
 .اﻟﺜﺎﻟﺜﺔ اﻟﺴﺎﻋﺔ
 , اﻟﻜﻮﻟﺴﺘﺮول ,اﻟﺒﻠﻴﺮوﺑﻦ, اﻻﻟﺒﻴﻮﻣﻴﻦ, اﻟﻜﻠﻴﺔ أﻟﺒﺮوﺗﻴﻨﺎت ﺗﺮآﻴﺰ ﻟﻤﺴﺘﻮى ﺗﻐﻴﺮ اى ﻓﻲ اﻟﻴﻨﺴﻮن ﻳﺘﺴﺒﺐ ﻟﻢ
  اﻟﺼﻮدﻳﻮم و اﻟﺒﻮﺗﺎﺳﻴﻮم , esatahpsohp enilakla dna TPG,TOG أﻧﺰﻳﻤﺎت و,  اتﻳﺪاﻟﺘﺮاﻳﺠﻠﻴﺴﺮ
 أﺛﺮ ﻟﻠﻴﻨﺴﻮن ﺑﺎن اﻟﻘﻮل هﻨﺎ ﻳﻤﻜﻨﻨﺎ وﻣﻦ اﻟﺴﻠﻴﻤﺔ أو اﻟﺴﻜﺮي ﺑﻤﺮض  ﻤﺼﺎﺑﺔاﻟ ﻟﻠﻔﺌﺮان اﻟﺪم ﺑﻼزﻣﺎ ﻓﻲ
 .   ﺳﺎم ﻏﻴﺮ ﺑﺄﻧﻪ و اﻟﺴﻜﺮي ﻟﻤﺮض ﻣﻌﺎﻟﺞ
 ,اﻟﺠﻠﻮآﻮز ﻣﺴﺘﻮى ﻓﻲ ارﺗﻔﺎع ﺳﺠﻠﺖ اﻻﺳﺘﺮﺑﺘﻮزﻳﺘﻮﺳﻦ ﻣﺎدة ﺑﻮاﺳﻄﺔ إﻣﺮاﺿﻬﺎ اﻟﺘﻲ  ناﻟﻔﺌﺮا
 ﺗﻐﻴﺮ أى ﻳﺴﺠﻞ ﻟﻢ و اﻟﺠﺴﻢ وزن و  اتﻳﺪاﻟﺘﺮاﻳﺠﻠﻴﺴﺮ , اﻻﻟﺒﻴﻮﻣﻴﻦ ﻓﻲ واﻧﺨﻔﺎض اﻟﻴﻮرﻳﺎ و اﻟﻜﻮﻟﺴﺘﺮول
 اﻟﻜﺮﻳﺎﺗﻨﻴﻦ , اﻟﺒﻠﻴﺮوﺑﻦ ,esatahpsohp enilakla dna TPG,TOG أﻧﺰﻳﻤﺎت , اﻟﻜﻠﻴﺔ أﻟﺒﺮوﺗﻴﻨﺎت ﻓﻲ
ix 
 وﺧﻔﺾ اﻟﺴﻜﺮي ﻣﺮض ﻟﻤﻌﺎﻟﺠﺔ واﻋﺪ ﻋﺎﻣﻞ اﻟﻴﻨﺴﻮن ﻳﻜﻮن أن ﻳﻤﻜﻦ ﻟﺬا اﻟﺼﻮدﻳﻮم و  ﻮﺗﺎﺳﻴﻮماﻟﺒ ,
                  .اﻟﺴﻜﺮي ﻣﺮﺿﻰ ﻋﻨﺪ ﻣﺴﺘﻮاﻩ
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Introduction 
 
The use of the herbs for therapeutic purposes in different parts of the world dates 
back to immemorial times. In developing countries, like Sudan, where people live in 
communities far away from each other, the inhabitants used to be short of or almost 
deprived of proper medical care. The most common disease around the world is 
diabetes mellitus according to World Health Organization (W H O) and many 
people had used herbs to treat it, some known herbs were used to treat diabetes 
mellitus .Some studies revealed valuable therapeutic activities and pharmacological 
nature as well as nutritional values of these herbs.  
A recent study carried out by Ajit et al. (2000) showed the activity of Anise ash in 
lowering glucose blood level in  glucose tolerance test for normal rats , also in a 
separate study carried out by Krediyych et al. (2003) exhibited the efficiency of 
Anise in increasing the activity of Na+,K+ ATPase and consequently the sodium 
gradient needed for sugar transportation .Therefore it is appropriate and justifiable 
to undertake an investigation on P.anisum antidiabetic effect in normal and diabetic 
rats  
This investigation is intended to study the effect of feeding P.anisum seed on 
diabetic and normal rats by monitoring biochemical parameters. 
Objective: 
This study is undertaken: 
-To evaluate the hypoglycemic and anti-diabetic effect of P.anisum on normal 
rats. 
-To evaluate the hypoglycemic and anti-diabetic effect of P.anisum on diabetic 
rats. 
- To evaluate the toxicity of the P.anisum. 
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Chapter One 
1.                                  Literature Review 
1.1. Pancreas  
1.1.1 Pancreas gross anatomy 
In man, the pancreas is an elongated, tapered organ located across the back of 
abdomen, behind the stomach. The right side of the organ (called the head) is the 
widest part of the organ and lies in the curve of the duodenum (the first section of 
the small intestine). The tapered left side extends slightly upward (called the body 
of the pancreas) and ends near the spleen. 
1.1.2 Pancreas histological structure 
 The pancreas consists of exocrine and endocrine cells. The former are acinar 
cells, which are grouped into lobules forming the ductal system, which eventually 
point into the main pancreatic duct. The endocrine pancreas consists of hormone-
producing cells arranged in nets or islets – the islets of langerhans. They do not 
connect directly to the duct system (Kumar and Clark, 1988) 
1.1.3 Pancreas function  
Pancreatic acini synthesize digestive enzymes, which are stored in secretary 
granules and released by exocytosis in response to stimulation by several 
hormones. The islet of langerhans is composed of four types of cells each of 
which synthesizes and secreted a distinct poly-peptide hormones. Insulin in the β 
cell ,glucagons in the A-cell,somatostatin in the D-cell and pancreatic poly- 
peptide in the PP or F- cell , makes up 60% to 80% of islet and form its central 
core  .There are four main types of islet cells and these have different secretary 
granules in their cytoplasm:   
β – cells, which are the most common cells, produce insulin 
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α – cells, produce glucagons 
D –cells produce somatostatin 
PP cells produce pancreatic polypeptide (PP) 
A number of other hormones (e.g. bombestin, neuropeptide, Y and galanin) are 
present in pancreatic neurons and probably act as neurotransmitters (Kumar and 
Clark, 1988). 
1.2. Insulin  
1.2.1 Structure and secretion  
 Insulin is key hormone involved in the storage and controlled release within the 
body of chemical energy available from food. It is coded for on chromosome 11 
and synthesized in the β cells of pancreatic islets. Insulin consists of A and B 
chains linked by disulphide bonds as shown in figure 1 (Kumar and Clark, 1988). 
The synthesis, intracellular processing and secretion of insulin by the β cell are 
typical to many peptide hormones. The manufacture and release of insulin from β 
cell is triggered by the metabolism of glucose entering the β cell , generates ATP; 
and ATP closes potassium channels in the cell membrane.  The cell membrane 
depolarizes allowing calcium ions to enter the cell via calcium selective channels 
in the membrane. The rise in intracellular calcium triggers activation of calcium-
dependent phospholipids protein kinase which, via intermediary phosphorylation 
steps, leads to fusion of insulin-containing granules with the cell membrane and 
exocytosis of the insulin-rich granule contents. Similar in many other endocrine 
cells secretion, insulin enters the portal circulation and is carried to the liver, its 
prime target organ.  About 50% of secreted insulin is extracted and degrade in the 
liver, kidneys break down the residence, and c-peptide is only partially extracted 
by the liver and hence provides a useful index of the rate of insulin secretion, but 
is mainly degraded by kidneys (Kumar and Clark, 1988). 
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Figure 1: Insulin Structure, A and B chains linked by disulphide bonds 
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1.2.2 Insulin function 
The actions of insulin have been known for quite sometime (Steiner, 1977).Insulin 
function include membrane transport of glucose, amino acids and certain ions; 
increased storage of glycogen; formation of triglycerides; stimulation of DNA, 
RNA and protein synthesis.  
Once in the blood, insulin controls glucose homeostasis by stimulating the uptake 
of glucose into skeletal muscle and, to a lesser extent, into liver and adipose 
tissue. In muscle and adipocytes this uptake is mediated by the so-called insulin-
sensitive glucose transporter GLUT-4, a process that is not yet understood. Other 
processes in the regulation of glucose homeostasis are: alterations in glycogen 
metabolism in muscle and liver and decreased gluconeogenesis in the liver. The 
enzymes involved in the insulin-regulated processes of glucose metabolism appear 
to be regulated by (de)phosphorylation of serine and/or threonine residues (Lee 
and Pilch, 1994). 
1.2.3. Other pancreatic hormones function 
Three other peptide hormones are produced in the islets of Langerhans in the 
pancreas:  
1.glucagon, consisting of 29 amino acids, in the A cells;  
2.somatostatin, a cyclic 14 amino acid polypeptide, in the D cells;  
3.pancreatic polypeptide, 36 amino acids with an amide C terminus, in the PP 
cells.  
Glucagon antagonises most of insulin's actions, while stimulating insulin 
secretion. Somatostatin inhibits the three other islet hormones and a range of 
hormones from different origins. Pancreatic polypeptide inhibits pancreatic 
secretion altogether (Johnston et al., 1988). 
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1.3 Diabetes mellitus 
Diabetes mellitus is a syndrome characterized by chronic hyperglycemia that is 
due to relative insulin deficiency, or resistance, or both.  It is affects more than 30 
million people worldwide. Diabetes is usually irreversible and although patients 
can have a reasonably normal lifestyle, its late complications result in reduces life 
expectancy and considerable uptake of health resources. Macro-vascular disease 
caused by diabetes mellitus leads to an increased prevalence of coronary artery 
disease (Kumar and Clark, 1988). 
1.3.1Diabetes mellitus in domestic animals: 
Diabetes mellitus is frequently found in the dog (1 in 152), and cats (1 in 800), 
although it has been reported in horse, cattle, sheep and pigs. The fundamental 
defect in domestic animals is an absolute or relative lack of insulin .As a result of 
this deficiency in insulin ,the animal is unable to utilize glucose .Consequently  
hyperglycemia is constant findings in diabetic animal. Clinical signs typically 
associated with diabetes include polydipsia, polyurea, increased appetite and 
weight loss .These classic signs of ketosis including anorexia; vomiting, 
weakness, lethargy and increase respiratory rate (Coles, 1986).  
1.3.2 Classification of diabetes mellitus 
Most patients can be classified clinically as having either insulin –dependent 
diabetes mellitus (IDDM or Type 1) or non-insulin dependent diabetes mellitus 
(NIDDM or Type 1I). In 1979, the National Diabetes Data Group formally 
classified diabetes mellitus and other categories of glucose intolerance as follows: 
1.3.2.1 Type I insulin-dependent-diabetes-mellitus (IDDM):  
Since this type usually occurs in juveniles, it was previously called juvenile 
diabetes. It can, however, start at any age. Patients usually present with easily 
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recognizable symptoms, so diagnosis is not difficult. Genetic determinants seem 
important for the onset in most patients, with environmental factors a close 
second. Abnormal immune responses (e.g. in normal childhood diseases like 
mumps) and autoimmunity are thought to play an etiologic role.  
1.3.2.2 Type II noninsulin dependent diabetes mellitus (NIDDM): 
This type can become recognizable at any age, although it can be asymptomatic 
for years and thus usually presents in patients over 40 years of age. Often only the 
complications seen after years of having diabetes, like neuropathy and cataracts, 
cause a diagnosis to be made. Occasionally people are diagnosed as a direct result 
of population studies, e.g. Mooy et al. (2005), a study in Hoorn, the Netherlands. 
This research into the prevalence of NIDDM and predictors for the development 
of the disease resulted in 106 newly diagnosed diabetics out of 2,484 participants 
between age 50 and 74. Not only age is an important factor in NIDDM, the 
genetic basis of NIDDM seems even stronger than that of IDDM, and it is 
aggravated by environmental factors. Moreover, 60 to 90% of all NIDDM patients 
in the Western world are obese, which should be seen as an indicator for sub 
classification of the type II diabetes. Symptoms are usually at least partly 
alleviated by weight loss.  
1.3.2.3 Gestational diabetes mellitus (GDM). 
There are two ways in which diabetes mellitus and pregnancy can occur 
simultaneously. One is where a previously diagnosed diabetic woman becomes 
pregnant, which involves certain risks for both mother and child. The other is in 
gestational diabetes, when a pregnant women becomes diabetic at some stage 
during pregnancy, because of the pregnancy and most commonly only for the 
duration of the pregnancy. It is easy to see the origin of problems in both cases, if 
one considers the fact that even in a normal pregnancy the third trimester is a 
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permanent state of mild hypoglycaemia because all organs have to work harder 
than normal, some up to 50%. Sometimes the pancreas functions sub-optimally. 
This means that the pregnant woman does not produce enough insulin herself, and 
the fetus will start to produce insulin to attain an acceptable maternal insulin level. 
This means the production of more fetus urine into the amniotic fluid. At the same 
time the level of growth hormone in the fetus rises along with the fetus insulin 
level (Remmers, 1994). This causes macrosomia (birth weight >4,000 grams), 
which may cause problems at birth. A Glucose tolerance test usually points out the 
need for diet or insulin therapy. Oral hypoglycaemic treatment cannot be used by 
a pregnant diabetic (Drury, 1988). Even after insulin treatment for GDM, most 
pregnant women return to normal glucose tolerance after delivery. If this is not the 
case, they have acquired clinical diabetes. From the previously gestational 
diabetics, 40% acquire overt diabetes mellitus within 20 years (Coustan, 1993) so 
they should be kept under some sort of observation. 
1.3.2.4. Other types of diabetes. 
Diabetes forms part of certain other conditions and syndromes, whether obviously 
an etiologically related or not. This class can be subdivided according to known or 
suspected a etiological relationships, where diabetes may be secondary to 
pancreatic disease (neonatal or later on in life), hormonal abnormalities which 
may have either hypoinsulinaemia or hyperinsulinaemia as a consequence, the 
administration of certain hormones, drugs and chemical agents, of which oral 
contraceptives, tricycle antidepressants and marijuana are but a few, insulin 
receptor abnormalities, either in the number of receptors or their affinity for 
insulin, or even because of the presence of antibodies to receptors (with or without 
associated immune disorders), certain genetic syndromes, e.g. metabolism 
disorders, insulin resistance, hereditary muscle disorders and cytogenic disorders 
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like Down's syndrome and  other types, of which diabetes associated with 
malnourished populations is the most prominent example 
It may also come secondary to drug administration or other disease or may occur 
during pregnancy (gestational diabetes mellitus).On rare occasions, diabetes may 
also result from point mutations in the insulin gene. In the diabetic patient with 
insulin deficiency or insulin resistance and hyperglucagonemia, there is an 
increase in gluconeogenesis and glycogenolysis, a decrease in peripheral glucose 
uptake, and a decrease in conversion of glucose to glycogen in the liver. 
1.3.2.4.1. Impaired-glucose-tolerance (IGT). 
For the diagnosis of impaired-glucose-tolerance (IGT), an oral glucose tolerance 
test is essential. The criteria for this classification lie between those for normal 
subjects and diabetics. Consequently, the seriousness of the disorder is 
intermediate between normal and diabetic, with some clinical complications being 
completely absent while others, especially cardiovascular abnormalities, 
commonly present. Thus, IGT may have prognostic implications that should not 
be overlooked, especially in seemingly healthy individuals. Like overt diabetes, 
IGT can be linked to numerous disorders and obesity. Patients with IGT do not 
necessarily proceed to develop clinical diabetes; many return to normal glucose 
tolerance for no apparent reason while others stay in the IGT class for many years. 
Apart from the clinical classes mentioned above, there are two so-called statistical 
risk classes. 
1.3.2.4.2. Previous abnormality of glucose tolerance. 
This class is restricted to those persons who have normal glucose tolerance but 
have previously demonstrated diabetic hyperglycemia or IGT either spontaneously 
or in response to an identifiable stimulus. Re-classification of gestational 
diabetics, former obese diabetics who have normal glucose tolerance after weight 
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loss and temporarily hyperglycaemic patients (due to trauma or injury) into this 
class is a useful tool for facilitation of follow-up of such patients. The likelihood 
of such persons developing clinical diabetes again should be considered to be 
increased.  
1.3.2.4.3. Potential abnormality of glucose tolerance (Pot AGT). 
Persons who have never exhibited abnormal glucose tolerance but who are at 
substantially increased risk for the development of diabetes should be classified as 
PotAGT. Certain risks for development of IDDM and NIDDM are well 
established, such as being a relative of an IDDM or NIDDM diabetic or belonging 
to certain ethnic or racial groups, although the degree of risk for any of the 
specific circumstances is much less clear.  
1.3.3 Biochemical changes associated with diabetes mellitus: 
  Lack of insulin causes significant disturbance of carbohydrate, protein and fat 
metabolism (Kumar, 1988). 
1.3.3.1Disturbance in carbohydrate metabolism 
The disturbance in carbohydrate metabolism is due to the fact that the liver and 
skeletal muscles can not store glycogen and the muscles are unable to utilize 
glucose .When the kidney threshold for glucose is exceeded , glucouria occurs 
with consequent increase of water excretions and disturbances of electrolyte and 
water balance.  
 
1.3.3.2 Disturbance in the protein metabolism: 
 
Protein metabolism in the liver is also deranged and an excessive amount of 
protein is transformed into carbohydrate (Wilson et al., 1975)  
1.3.3.3 Disturbance in fat metabolism: 
 
In addition, the amount of fat metabolized by the diabetic patient is excessive, and 
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since normal fat catabolism can only proceeds at a limited rate, Ketone bodies are 
present in the blood and the urine in much large amount than normally; these 
substances are excreted in the urine as β – hydroxybutyric acid and acetoacetic 
acid and as acetone in the breath (Wilson et al., 1975). The liver produces ketone 
bodies by oxidation of the free fatty acids synthesis and this decreases the 
production of Ketone bodies ,conversely , glucagons stimulates ketone body 
production by stimulating lipolysis and increasing fatty acid oxidation .In the 
diabetic patient ,particularly with type 1 diabetes , the consequences of insulin 
deficiency and glucagons excess provide a hormonal milien that favors 
ketogenesis and in the absence of appropriate treatment , may lead to ketoneamia 
and acidosis . 
 
Insulin also interacts with the capillary endothelium to activate lipoprotein lipase, 
the enzyme that hydrolyses the triglycerides present in very –low –density 
lipoprotein VLDL and chylomicrons ,resulting in release of intermediate –density 
lipoprotein IDL particles (Taskinen,1987) these ILD particles are converted by the 
liver to the more cholesterol –rich – density lipoprotein LDL .In the untreated or 
under treated diabetic patient , hypertriglycridemia may occur as a result of the 
decrease removal of VLDL secondary to decrease activity of lipoprotein lipase  
In addition, deficiency of insulin may be associated with increased production of 
VLDL. 
1.3.4 Treatment of diabetes mellitus 
1.3.4.1Earliest treatment of diabetes mellitus 
Until the 1910s opium was the only widely used medicine in the treatment of 
diabetes mellitus. However, this could only dull the patients' despair, but did 
nothing to cure or treat. Further treatment consisted of more or less trendy diets. In 
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the late 1850s Piorry advised the use of extra sugar, to compensate for the loss of 
sugar into the urine. This 'eating a lot to compensate' was practised until the early 
1900s. In Paris under German siege, in 1870, Bouchardat noticed that rationing of 
food caused the disappearance of glycosuria in diabetic patients, while exercise 
also seemed to have a positive effect. The idea settled that may be the body should 
be put under as little metabolic strain as possible by limited eating. 
At the time of the earliest tests of pancreatic extracts in the treatment of diabetes 
mellitus, America had two leading diabetologists who did not believe in pancreas 
therapy. They were Allen and Joslin. They both practiced 'starvation treatment' 
where the patients are undernourished for a certain amount of time. They argued 
that apart from the carbohydrate metabolism, the protein and fat metabolisms in 
diabetic patients were also affected. By cutting down on food until the patient's 
body was relieved of all metabolic strain, and then slowly building up again until 
a reasonably healthy diet was achieved, many diabetics could live years longer. 
Some patients, however, did not even tolerate the minimum amount of food (the 
'living diet'), and succumbed quickly. 
1.3.4.2 Modern treatment of diabetes mellitus with insulin 
Since 1922, a lot of research has gone into the improvement of insulin therapy, 
both in terms of improved insulin preparations and ease of use. 
Achieving purity was the first challenge. Abel discovered insulin could be 
crystallised, which became standard procedure in insulin purification only after. 
Scott (1934) established that zinc was needed in order to crystallise insulin in 
rhombohedral form, a discovery inspired by his observation of zinc in the 
pancreas. Another crystallisation step reduced allergic reactions (Jorpes, 1949). 
Chromatographic techniques started to play a role in the 1960s, leading to the first 
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chromatographically purified insulin and monocomponent of insulin 
(Schlichtkrull et al., 1970).The search for new insulin preparations with various 
desired properties was approached in many different ways. At first it was thought 
the number of injections needed every day could be reduced by using insulins 
with a retarded uptake from the injection site, which could be achieved by 
introducing basic additives as in protamine and isophane insulin (Hagedorn et al., 
1936). Addition of compounds like surfen or globin to acid insulin solutions, 
which produce heavily insoluble complexes upon neutralisation in tissue fluids, 
and complex formation of zinc with neutral insulin suspensions, had the same 
effect. However, the need for strict metabolic control in prevention of long-term 
complications called for the reinstatement of multiple injections, along with the 
development of rapid-acting insulin for the relief of the glucose-surge just after 
meal times, and mixtures of rapid-acting and intermediate-to-long-acting insulins. 
Developments in this field include Rapitard and Actrapid (Schlichtkrull, 1959 ; 
Schlichtkrull et al., 1961).The duration of action could also be influenced by the 
physical state and size of the insulin particles. Ultralente (Hallas et al., 1956) is an 
example of a long-acting crystalline insulin preparation. Initially, only bovine 
insulin was used for crystalline preparations, having a slightly longer action than 
porcine insulin in crystalline form. Gradually, longer acting porcine preparations 
became available. Then, in 1979, recombinant DNA techniques made it possible 
to produce human insulin in Escherichia coli (Goeddel et al., 1979). Amazingly, 
this was done without knowledge of the nucleotide sequence of the human insulin 
gene. Crea et al. (1978) had chemically synthesized two separate genes for chain 
A and B (77 and 104 base pairs for 21 and 30 amino acids, respectively, plus start 
and stop codons and restriction site bases following nucleotide sequences that had 
been designed from the amino acid sequences. By designing the nucleotide 
sequences the way they did, there was no need to produce every possible tri-
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nucleotide separately. They produced 29 oligonucleotides, made from carefully 
chosen di-, tri- and tetra nucleotide building blocks. Goeddel et al. (1979) describe 
the actual assembly of the genes, the subsequent construction of the plasmid, and 
the expression and characterizations of the product. They showed that the amino 
acid content of the product is indistinguishable from that of porcine insulin. It took 
another year before the actual nucleotide sequence of the human insulin gene was 
published by Bell et al. (1980). Only 21 out of 51 of the codons used by Crea et 
al. (1978) turned out to be the same in the correct DNA-sequence. 
Production of human insulin could also be achieved by conversion of porcine 
insulin (Markussen, 1982) or biosynthesis in Saccharomyces cerevisiae rather 
than E. coli (Markussen et al., 1986). Over the years, the production of many 
therapeutic insulins has involved chemical alteration of the molecule. Nowadays, 
modified insulins can be synthesized by mutation of the genes used in E. coli or S. 
cerevisiae, thus facilitating structural and functional studies. But apart from the 
scientific possibilities opened up by the availability of recombinant insulin, there 
was a pressing need for a new source of the protein, because the demand for 
insulin for therapy was outgrowing the supply of slaughter pancreases for the 
isolation of insulin. Even now (Kott, 1996) the major insulin manufacturers are 
not able to provide insulin for every area of the world, and cheaper beef and pork 
insulin is still produced, especially for third world countries. 
Because of the varying needs of diabetic patients, insulin has to be available in 
multidose quantities. This requires the addition of antimicrobial preservatives. 
Banting and best used tricresol to that effect, and to this day phenol and 
derivatives like m-cresol and methylparaben are used throughout the range of 
therapeutic agents. Other additives include sodium chloride or glycerol as isotonic 
agents, and certain buffers (Brange, 1987). 
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Alongside research into better and purer preparations, came the development of 
techniques of administering them. At the time of Banting and Best it was already 
established that oral therapy did not have any desired effect, and that 
subcutaneous or intravenous injections were the only option. Many other routes of 
absorption were tested, including rectal administration and absorption by 
mucosae. Success was limited. Even with more modern technology of aerosol 
powder (Wigley et al., 1971), surfactants (Hirai et al., 1981), liposome-enclosure 
(Dapergolas and Gregoriadis, 1976) or polymer-crosslinking (Saffran et al., 1986) 
the desired efficiency and bioreactivity has not been achieved. The subcutaneous 
implantation of vinyl-ethylene copolymer pellets (Creque et al,, 1980) or 
biodegradable insulin-albumin microbeads (Goosen et al., 1983), releasing insulin 
slowly and constantly over a longer period of time, seems more promising. Most 
recently, reports have appeared on glucose-responsive insulin release from certain 
polymeric systems (Shiino et al., 1995). However, the only techniques in actual 
clinical use are based on injections. Hospitals operate systems of continuous 
infusion, either according to continuously measured glucose concentrations 
(Albisser et al., 1974) or a pre-programmed schedule. These insulin pumps are not 
yet available to the general public, although additional research is done on 
implantable pumps (Buchwald et al., 1981). Today's most patient-friendly 
portable insulin delivery is the NovoPen, which has reduced injections to just 
pressing a button. Most diabetics seem to prefer this to other available options 
(Jefferson et al., 1985). 
         1.3.5 Inducing Diabetes Mellitus by Cytotoxic agents: 
 
           Specific cytotoxic agents such as alloxan or streptozotocin can selectively destroy 
the β –cells of pancreas, injection of these agents produces a form of "Chemical " 
diabetes which closely resembles diabetes due to surgical removeal of the 
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pancreas. Streptozotocin is a broad –spectrum antibiotic with anti – tumor and 
oncogenic properties which is widely used as a diabetogenic agent in experimental 
animals (Herr et al., 1967). This action is mediated by beta – cell destruction, 
which results in the development of an insulin depentedent syndrome . 
1.4 Medicinal Plants 
Recently, many experimental and clinical trials were made to detect the 
hypoglycemic and anti-diabetic effects of many medicinal plants used in the 
medicine for the treatment of diabetes mellitus. 
Earlier studies on the leave of Zizyphus lotus carried by (Glombitza et al., 1994) 
reported that Zizyphus lotus caused a significant reduction in fasting serum 
glucose, and improved glucose utilization in alloxan diabetic rabbits without 
affecting serum insulin and peptide levels. 
Streptozotocin induced diabetic and non diabetic rats were given an oral 100 
mg/kg dose of butanol fraction prepared from the methanolic extract of leaves of 
Zizyphus spina christi, or 10 mg/kg of christinin – A, the principle saponin 
glycoside contained in this butanol fraction, treatments were continued daily for 
period of 1 week or 1 month, whereas no significant effects were observed in non-
diabetic ( control) rats, both the butanol fraction and christinin-A ( long 
treatments) significantly reduced serum glucose levels, inhibited liver phosorylase 
and glucose -6- phosphates activities, significantly increased serum pyrurate level 
and line glycogen content, and improved glucose utilization in the diabetic rats.  
The butanol fraction was also found significantly increased serum insulin and 
pancreatic -c- AMP levels in diabetic rats. 
The chloroform and methanolic extracts of seeds of Citrullus colocynthis and the 
ethanolic extracts of leaves and pulp were investigated for pharmacological effects 
in normal and diabetic ( streptozotocin- induced) rats and in isolated organs of rats 
and rabbits.  Neither seed extract had any effect on fasting glucose level in normal 
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or diabetic rats and they found no effect in the oral glucose tolerance test ( Wasfi, 
1994) .investigated the potential hypoglycemia effect of the decoction of Jumibers 
communis berries on normal and streptozotocin – diabetic fanals Wister rats, 
diabetic rats which were given the decoction at a dose of 125mg of total berries 
per kg body weight for 24 days, showed a significantly reduced blood glucose 
levels, lost less weight and had a significant lower mortality index compared with 
untreated diabetic rats, oral administration of decoction at single dose of 250 and 
500 mg/kg had no effect. Studies on intestinal glucose absorption, perphenral 
glucose consumption and pancreatic action indicated that the hypoglycemic 
activity of J.communis berries is due to an increased consumption of peripheral 
glucose and or increased glucose – indeed insulin secretion. 
1. 4.1 Pimpinella anisum  
       Family: Apiceae ( Umbelliferae) 
       Genus: Pimpinella  
       Species: Pimpinella anisum 
       Synomons names : Anisum vulgare Gaertn and Anisum Officinarum Moench 
        English name:  Anise or Aniseed 
        Arabic name: Al yansoon 
The origin locations of Pimpinella are Egypt and Greece, and then it spread in 
different part of the world.  In Sudan we found it in northern state and with 
possibility to grow in Khartoum state. 
1.4.2 Plant description: 
     Anise or sweet Alice belongs to umbelliferae family.  Anise is an annual herb 
that reaches heights of about two feets, leaves and seeds produced in large loose 
clusters.  The upper leaves are very lacy while the lower leaves are broader up to 
one inch wide resembling parsley. Seeds are oblong about 1/6 inch long and 
curved, fresh leaves are used for flowering and garnishing, but the important 
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articles of commerce are seed and oil obtained from them. 
1.4.3 Phytochemistry: 
Phytochemistry screening of seeds and leaves of pimpinella revealed the presence 
of acetaldehyde , alpha pinene, alpha terpinean, alpha zingibaren, anisealdenyde 
anise-acid, anise-alcohol, ascorbic-acid, bergapter  B.bisabolene, pinene, boron, 
caflicaeid, calcium, comphore, chlorogen-acid, choline, copper, carvone, 
dianethole, estrogole, eaglal, fiber, limonen, livaloal, magnesium, manganese, 
mannitol and  transe-anethole. 
1.4.4 Biological activities  
1.4.4.1 Anti- microbial activity 
Pimpinella has antimicrobial activity against bacteria and fungi.  Hexane and ethyl 
acetate extraction of pimpinella tuberous roots exhibit abroad spectrum of 
antimicrobial activity and were analysed for different photochemical. 
1.4.4.2 Anti- Oxidant activity: 
Antioxidant activities of Pimpinella was determined using the free radical alpha-
alpha-diphenyl-beta-picrylhydrazyl(DPPH) and preformed radical  monocation  
2.2.-azino-bis(3-ethylbenzothiazoline-6-sulphonicacid).Pimpinella had antioxidant 
capacities in a range comparable to that of alpha tocophand, BHA, ascorbic and 
Trolox, which were used as reference antioxidants. 
1.4.4.3 Acqusition and expression of morphine: 
Pimpinella essential oil has effect on acquisition and expression of morphine 
indeed condition place preterene in mice, and it appeared that the essential oil of 
the pinpinella may reduce the morphine effects via a GABA ergic mechanism. 
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Figure 2: P.anisum flower 
 
 
 
Figure 3: P.anisum (flowering plants) 
 
 
 
Figure 4: P.anisum Seeds 
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Chapter Two 
2.      Material and Methods 
 
This works has been conducted in the department of Pharmacology in Medicinal 
and Aromatic Plants Research Institute (MAPRI) National Center for Research, 
and department of Biochemistry Faculty of Veterinary Medicine, University of 
Khartoum. 
2-1 Materials: 
2-1-1 Experimental animals: 
Wistar albino rats of either sex were used. Twenty four rats were divided into four 
groups on the basis of body weights in such way that the average weight of each 
group was 91-100g. 
2-1-2 Plant: 
Pimpinella anisum was purchased from local market .It was dried in the shade. 
The seeds were the part used in experimentation. 
2-1-3 Experimental design: 
The groups were designated as A, B, C and D and six rats were included in each 
group. 
- The rats of groups A and B were kept as normal control. 
- The rats of groups C and D were injected with 60mg /k body weight Streptozot- 
ocin dissolved in citrate buffer pH 4.5 to induced diabetes 
2-1-4 Feeding Program: 
Each group was kept in a cage and was supplied with feed composed of meat and 
flour plus salt .The feed was available at the rate of 36 g per day in each cage. The 
four groups were fed as followed as follows: 
Group A: received flour and meat diet + salt 
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Group B: received flour and meat diet + salt + 15% of total diet was replaced by 
P.anisum seed powder 
Group C: received flour and meat diet + salt 
Group D: received flour and meat+ salt+15% of total diet was replaced by 
P.anisum seed powder.  
Table No 1: Experimental design and feeding program 
Description Group A Group B Group C  Group D 
Numbers of rats  6 6 6 6 
Induction of diabetes - - + + 
Feeding P.anisum 
seeds 
- + - + 
 
2-1-5 Reagents and chemicals 
Reagents used for estimation of biochemical parameters were obtained from 
Crescent Diagnostics Co. 
- Streptozotocin was purchased from Sigma Co. 
2-1-6 Instruments: 
The instruments used in the experimentation included: 
  WTW – pH meter. 
 CIBA - Corning colorimeter- Model 252 
 I E G – Centra – 4 B centrifuge. 
 SB Water bath for the incubation of samples 
 FINN pipettes, digital micropipette  
 Heparinzed capillary tubes 
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2-1-7 Samples collection 
One to two ml of blood were drawn out from orbital plexus of rats by capillary 
tubes in fluorinated test tubes from each rat at day 2 to estimate glucose and 
checking whether the diabetes was induced or not .  The rats were weighted every 
week to monitor its weight .At day 21st the blood was collected from the rats and 
plasma was separated to perform glucose tolerance test. At day 22nd the rats were 
sacrificed and blood was collected and centrifuged at 3000 rpm for 5 minuets to 
separate plasma. The plasma was used to estimate some biochemical parameters. 
2-2-Methods 
2-2-1: Biochemical methods: 
Rats were subjected to fasting for 18 hours period pro experiment .After that the 
level of plasma glucose was determined at 0 h, then they were injected by 50% 
glucose solution at dose of 2g/kg and plasma glucose level was monitored 1 h, 2h 
and 3 h after injection. 
2-2-1-1 Determination of glucose  
Glucose concentration in the plasma was determined by an enzymatic method as 
described by Trinder (1969) 
Principle; 
Glucose is determined after enzymatic oxidation in the presence of the enzyme 
glucose oxidase. The hydrogen peroxides formed react under catalysis of 
peroxidase, with phenol and 4. aminophenazone to from a red violet quinoneimine 
dye as indicator. 
Glucose +O2 +H2O       GOD        gluconic acid +H2O2  
2H2O2 +4.aminophenaone +phenol    POD         quinoneimine +4H2O 
Reagent: 
Phosphate buffer 0.1mol /l pH 7 
Phenol 11mmol/l 
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4. Aminopherazone 1.5 KU/I 
Peroxidase 1.5 KU /1 
Standard:  
Glucose 100 mg / dl 
Procedure: 
Twenty µl of each standard and sample were pipetted into separated two test 
tubes. 2000 µl of the reagent were added to each tube and they were mixed and 
incubated for 5 minutes at 37°C in water bath. The absorbance of the standard     
A (std) and of the sample A (s) were measured against the reagent blank at the wave 
length 490 nm by CIBA Corning Colorimeter- Model 252. 
 
Calculation: 
Glucose concentration (mg/dl) = A (s) ÷A (std) X100 
 
2.2.1.2 Determination of total cholesterol: 
The cholesterol concentration was estimated by an enzymatic method, which 
measures the total cholesterol concentration in the serum or heparinzed plasma as 
described by Richmond (1973) 
Principle: 
Cholesterol and its esters are released from lipoproteins by detergents .Cholesterol 
esterase hydrolyzes the esters and H2O2 is formed in the subsequent enzymatic 
oxidation of cholesterol by cholesterol – oxidase according to the following 
reactions: 
Cholesterol ester +H2O cholesterol esterase   cholesterol + fatty acids  
Cholesterol+O2 Cholesterol oxidized Cholesten -3-on + H2O2 
2H2O2+phenol+4.aminophenazone peroxidase quinoneimine-dye+4H2O                                                     
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Reagents: 
-Reagent (buffer) R1: 
Pipes buffer pH: 6.9         90mmol /l 
Phenol                             26mmol /l 
-Enzyme reagent R2: 
Cholesterol oxidase          200 U/l 
Cholesterol esterase          300U/l  
Peroxidase                        1250U/l 
4. Aminophenazone           0.4mmol/l 
-Standard Reagent R4: 
Cholesterol                         200mg/l 
To prepare the working reagent, R2 were dissolved with the corresponding 
volume of buffer R1. 
 
Procedure: 
Twenty µl of the standard and sample were pipetted into two separated test tubes, 
2000 µl of the working reagent were added, mixed and incubated for 5 minutes at 
37°C in water bath .Absorbance of the sample A (s) and of standard A (std) were 
measured against a reagent blank at wave length 550 nm by CIBA Corning 
Colorimeter- Model 252. 
Calculation: 
Cholesterol concentration =A (s) ÷A (std) X standard concentration (200mg/ l)  
2.2.1.3 Determination of triglyceride  
 Triglyceride level in plasma was measured by an enzymatic method in which 
triglyceride are enzymatic hydrolyzed to glycerol as reported by Richmond (1973) 
and according to the following reactions: 
Triglyceride         Lipoprotein Lipase      glycerol + free fatty acids  
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Glycerol +ATP   Glycerol Kinase     Glycerol-3-Phosphate +ADP 
Glycerol-3-Phosphate+O2   Glycerol-3-phosphatase  Dihydroxy acetone phosphate +H2O2 
H2O2 +4-amino antipyxine +p-chlorophenol Peroxidase     4H2O +4 quinoneimine-dye  
Reagents: 
Buffer reagent (R1): 
Pipes buffer pH: 7.2                50mmol / l 
P-chlorophenol                        2mmol/l 
Enzymatic reagent (R2): 
Lipoprotein lipase                    150,000 U/l 
Glycerol Kinase                       800U/l 
Glycerol -3-p-oxidaese            4000 U/l 
Peroxidase                               440 U/l 
4-aminoamtipyrine                  0.7mmol / l 
ATP                                         0.3mmol / l 
Standard reagent (R3): 
Glycerol   200 mg /dl 
Working reagent: 
R2 were dissolved with the corresponding volume of buffer R1  
Procedure: 
Twenty µl of sample and standard were pipetted into two separated test tubes. 
2000 µl of the working reagent were added. They were mixed and incubated at 
37°C for 5 minutes in water bath .The absorbance of the sample A (s) and standard 
A (std) were measured against reagent blank at wave length 546 nm by CIBA 
Corning Colorimeter- Model 252. 
Calculations: 
Triglyceride concentration mg/dl= A (s) ÷ A (std) X standard concentration 
(200mg/dl)  
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2.2.1.4 Determination of plasma total protein:  
Photometric colorimetric method (Biuret method) was used to determine the total 
protein in the plasma. 
Principle: 
Protein in serum or plasma forms a blue violet complex when mixed with copper 
ions in alkaline solution .In Biuret reaction each copper ion binding with 5 or 6 
peptide bonds. Tartarat is added as a stabilizer and iodide is used to prevent auto 
reduction of the alkaline copper complex .The absorbance of this complex 
measured at 546 nm is proportional to protein concentration. 
Reagents: 
Biuret reagent: 
Sodium hydroxide               200mmol /l 
Potassium sodium tartarat    32mmol /l 
Copper sulphate                  18mmol /l 
Potassium iodide                 30mmol /l 
Standard                
 Protein                               8g/dl 
Procedure: 
The standard (0.02 ml) and the sample (0.02 ml) were pipetted into two separated 
test tubes. One ml of the Biuret reagent was added to each tube then they were 
mixed and incubated at 37°C for 5 minutes in water bath. Absorbance of sample 
(AS) and standard (A std) were measured against the reagent blank within 30 
minutes by CIBA Corning Colorimeter- Model 252 at wave length 546 nm. 
Calculation: 
Plasma total protein (g/dl) =AS ÷ A std X concentration of standard  
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2.2.1.5 Determination of plasma albumin: 
 Albumin concentration in plasma was determined by colorimetric test – BCG 
Method . 
Principle: 
Albumin binds selectively to dye bromocresol green at pH 4.2 .The absorbance of 
this blue / green complex at 546 nm is proportional to albumin concentration 
Reagents: 
Citrate buffer (pH 4.2)              7.5mmol/ l 
Bromocresol green                   180mmol/ l 
Sodium Azide                           0.05% 
Standard  
Albumin                                   4g/dl 
 
Procedure: 
The standard (0.01 ml) and the sample (0.01 ml) were pipetted into two separated 
test tubes. One ml of reagent was added to each tube. Then they were mixed and 
incubated in water bath for 8 minutes at 20-25°C. The absorbance of the sample 
(AS) and standard (A std) were measured against reagent blank by CIBA Corning 
Colorimeter- Model 252 at wave length 546 nm. 
Calculation: 
Albumin concentration (g/dl) = AS÷A std X concentration of standard  
2.2.1.6 Determination of creatinine  
Kinetic method without deproteinisation – Jaffe reaction was used to estimate the 
creatinine concentration in the plasma in this study.   
Principle: 
In the Jaffe reaction, creatinine reacts with alkaline picrate to produce a reddish – 
orange colour, the intensity of which at 490nm is directly proportional to 
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creatinine concentration  
Reagent: 
Picric acid                             35mmol/l 
Sodium hydroxide                  320mmol/l  
Standard  
Creatinine                               2mg/l 
Procedure: 
The standard (0.1) ml and the sample (0.1) ml were pipetted into two separated 
test tubes. Then one ml of the reagent was added to each tube, and in other two 
separated test tubes 0.05ml of sample and standard were pipetted, and 0.5ml of the 
reagent was added to each tube .Then the tubes were mixed well in each case 
Absorbance A1 was measured after 30 second for first two tubes, and after 2 
minutes the absorbance A2 was measured for second two tubes by CIBA Corning 
Colorimeter- Model 252 at wave length 490 nm. 
 
A =A2-A1 for each tubes. 
Calculation: 
Creatinine mg/dl =A (s) ÷A (std) X concentration of Standard. 
2.2.1.7 Determination of urea: 
Enzymatic colorimetric, endpoint- Berthelot method was used to measure the urea 
level in the plasma examined in this study 
Principle 
Urease catalyses the conversion of urea to ammonia. In modified Berthelot 
reaction, the ammonium ions react with mixture of salicylate, hypochlorite and 
nitroprusside to yield a blue – green dye (indophenol) the intensity of this dye is 
proportional to urea in the sample. 
Urea+H2O       Urease            2NH3+CO2 
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NH3+Salicilate + hypochlorite       nitroprusside   2-2Dicarboxy-indophenol 
Reagents: 
1. Phosphate buffer            120mmol / l 
   Sodium salicylate             60mmol/l 
   Sodium nitroprusside       5mmol/l 
    EDTA                             1mmol/l 
    Urease                             5KU/l 
2. Phosphate buffer              120mmol / l 
    Sodium hydroxide            400mmol /l 
    Sodium hypochlorite        10mmol/l 
3. Standard 
    Urea                                80 mg/dl   
Procedure: 
The standard (0.01) ml and the sample (0.01) ml were pipetted into two separated 
tubes .Reagent (1.0) ml was added to each tube then they were mixed and 
incubated in water bath for 5 minutes at 25°C after that 1.0 ml of reagent 2 was 
added to each tube . They were mixed and incubated for two minutes at 25°C . 
The absorbance of sample (AS) and standard (A std) were measured against the 
reagent blank by CIBA Corning Colorimeter- Model 252 at wave length 578 nm. 
Calculation: 
Urea (mg/dL) =AS÷A std X concentration of standard. 
2.2.1.8 Determination of bilirubin  
Bilirubin concentration in plasma was determined according to the method 
.Principle: 
Bilirubin in the presence of a sulphanilic acid diazonium salt forms a red coloured 
azo compound in alkaline solutions .The total and direct Bilirubin in plasma is 
determined using the method on which we can coupling it with diazotized 
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sulphanilic acid after the addition of caffeine and sodium benzoate . 
Reagents: 
Reagents (R1)- Sulphanic acid solution 
 Sulphanilic acid                   30mmol/l 
Reagent (R2)- Sodium nitrite solution  
Sodium nitrite                      50mmol/l 
Reagent (R3)- caffeine solution  
Caffeine                               100mmol/l 
Procedure: 
In three test tubes indicated as total, direct and blank ,200 µl of reagent (R1) was 
pipetted in each tube. Then one drop of R2, 2.0ml of R3 and 200 µl of sample were 
added into total tube. In direct tube ,one drop of R2, 2.0ml of saline and 200 µl of 
sample were added. In blank tube 2.0ml of saline and 200 µl of sample were 
added .The tubes were mixed and incubated for 5 minutes at 28°C. The 
absorbance of total and direct were measured against reagent blank by CIBA 
Corning Colorimeter- Model 252 at wave length 549nm. 
Calculation : 
Total bilirubin (mg/dl)  = Absorbance of total tube X17.5 
Direct Bilirubin (mg/dl) = Absorbance of direct tube X17.5 
Bilirubin (mg/dl) = Total – Direct  
2.2.1.9 Determination of alkaline phosphatase: 
 The concentration of alkaline phosphatase in the plasma was determined by 
optimized standard method . 
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Principle:  
p-nitrophenylphosphate+H2O     Alkaline phosphatase     phosphate+p-nitrophenol 
Reagents: 
Buffer 
Diethanolamine buffer           1 mol/l (pH 9.8) MgCl2 
Substrate 
p-nitrophenylphosphate                            10mmol/l 
Procedure: 
Half µl of the sample was pipetted into a test tube, then 3 µl of reagents were 
added and mixed, the initial absorbance was read and timer was started 
simultaneously. Then   the absorbance was read again after 1, 2, and 3 minutes at 
wave length 405nm by CIBA Corning Colorimeter- Model 252 
Calculation  
The alkaline phosphatase activity was calculated by the following formula 
U/l=3300 X –A 405nm/min Macro 
2.2.1.1. Determination of glutamic-oxaloacetic transaminase 
The activity of glutamic oxaloacetic transaminase was measured by Reitman  
methods. 
Principle 
Glutamic oxaloacetic transaminase is measured by monitoring the concentration 
of oxaloacetate hydrazone formed with 2, 4-dinitrophenylhydrazine. 
 α- oxoglutarate+L-aspartate    GPT                 L-glutamate+oxaloacetate 
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Reagents 
1-Buffer  
-Phosphate buffer             100 mmol/l, pH7.4 
-L-aspartate                      100 mmol/l 
-α- oxoglutarate                  2mmol/l 
2- 2,4dinitrophenyl hydrazine     2mmol/l 
3- Sodium hydroxide solution     0.4 mol/l 
 
Procedure: 
0.5ml of the Buffer and 0.1ml distilled water were pipetted in a test tube and 
labeled as reagent blank, 0.1ml sample and 0.5ml of the buffer were pipetted in 
another test labeled as sample then they were mixed and incubated for exactly 30 
min at 37 °C after that 0.5ml of 2,4dinitrophenyl hydrazine was added to each 
tube The absorbance of sample (A) against the reagent blank after 5 min was read 
at wave length 546 nm by CIBA Corning Colorimeter- Model 252. 
Calculation: 
The activity of GOT obtained from ideal Calibration curved for the absorbance 
against the activity.  
2.2.1.11. Determination of glutamic pyruvic transaminase (GPT): 
The activity of glutamic pyruvic transaminase (GPT) was measured by Reitman 
method. 
Principle: 
α- oxoglutarate+L-alanine       GPT                 L-glutamate+pyruvate 
Glutamic pyruvic transaminase is measured by monitoring the concentration of 
pyruvate hydrazone formed with 2-4-dinitrophenythydrazine. 
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Reagent 
Buffer  
Phosphate buffer                          100 mmol/l, pH 7.4 
L-alanine                                      200 mmol/l 
α- oxoglutarate                              2.0 mmol/l 
2,4-dinitrophenylhydrazine           2.0 mmol/l 
3- Sodium hydroxide solution     0.4 mol/l 
 
Procedure: 
Half ml of the Buffer and 0.1ml distilled water were pipetted in a test tube and 
labeled as reagent blank, 0.1ml sample and 0.5ml of the buffer were pipetted in 
another test labeled as sample then they were mixed and incubated for exactly 30 
min at 37 °C after that 0.5ml of 2,4dinitrophenyl hydrazine was added to each 
tube The absorbance of sample (A) against the reagent blank after 5 min was read 
at wave length 546 nm by CIBA Corning Colorimeter- Model 252 
Calculation: 
 The activity of GOT obtained from ideal Calibration curved for the absorbance 
against the activity 
2.2.1.12 Determination of sodium and potassium: 
The concentration of sodium and potassium in the plasma were determined 
according to the Standard Official Method of Analysis (A.O.A.C,) using Coring 
410, flame photometer 
Principle: 
Using compressed air, diluted plasma is sprayed as a fine mist of droplets into a 
non-luminous gas flame which becomes colored by the characteristic emission of 
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the sodium or potassium metallic ions in the sample. 
Light of wave length corresponding to the metal being measured is selected by a 
light filter or prism system and allowed to fall on a photosensitive detector system. 
The amount of light emitted depend on the concentration of metabolic ions present 
in the sample. 
Procedure:  
One ml of the sample was taken and diluted in a 50ml conical flask with distilled 
water. The standard of the KCl and NaCl were prepared by dissolving 2.54g, 
3.33g of KCl and NaCl respectively, each in 1000ml distilled water. Ten ml of 
this solution were taken and diluted with 1000 ml distilled water to give a 10 ppm 
concentration. The flame photometer was adjusted to zero degree using distilled 
water as blank and 100 degree using standard solution. Then the flame photometer 
reading was recorded for each sample. 
Calculation: 
Concentrations of the alkaline metals were calculated by the following equations: 
Mineral K or Na (%)=  [F.R X D.FX 100] 
                                       106 X S X10 
Where: 
FR=Flame photometer reading 
DF=Dilution factor 
S    =Sample weight  
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2.3 Statistical Design: 
According to completely randomized design the rats were divided into four groups 
(A, B, C and D).Each group contains 6 rat of similar body weight. The data were 
analyzed by one and two way ANOVA procedure according to SPS software. 
Each test was conducted at 5% level of significance. Means were separated by 
Duncan multiple range test. 
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Chapter three 
3                                           Result 
 
3.1 The effect of Streptozotocin injection on plasma glucose concentration of 
rats  
When wistar albino rats were injected with streptozotocin, the plasma glucose 
concentration in day 2 increased to (321 and 293.1) for group (C&D) respectively 
when compared with glucose level in day Zero , while the glucose level at day 2 
of control groups (A & B) remain the same when compared glucose level at day 
as shown in figure 3.                             
 
3.2 The effect of feeding P.anisum on plasma glucose concentration of normal 
and diabetic rats  
When P.anisum seeds powder was added to the diet of normal and diabetic rats, 
plasma glucose level measured after overnight fasting and then after 1, 2and 3 
hours after break fasting are shown in table 2. 
At 0h, there is no significant difference in glucose level between normal rats fed 
diet only (group A) and normal rats fed diet plus P.anisum powder (Group B), 
although the glucose level of P.anisum fed normal rats(Group B)was numerically 
lower than (group A) normal rat fed diet only (77.8 vs 71.8) 
The glucose level of diabetic rats(group C) at 0h was significantly higher than 
glucose level of normal rats fed diet only (group A) and  normal rats fed diet 
containing P.anisum(Group B). The glucose plasma concentration of diabetic rats 
fed diet containing P.anisum (group D) was significantly lower than glucose 
concentration of diabetic rats fed diet only(group C). 
At 1 hour, the plasma glucose concentration of normal rats fed diet only(group A) 
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and normal rats fed diet containing  P.anisum were similar(155.8 vs 153).While 
the plasma concentration of diabetic rats(group C) was significantly higher than 
normal rats (group A) , normal rats fed P.anisum (group B) and  diabetic rats fed 
diet containing P.anisum (group D). 
The plasma glucose level of diabetic rats fed P.anisum after 1 hour was 
significantly higher than plasma glucose level of normal rats fed diet only (group 
A) and normal rat fed diet containing P.anisum (Group B). 
Two hours after feeding of fasted rats ,the plasma glucose level of normal rats fed 
diet and P.anisum (Group B) was significantly lower than normal rats fed diet 
only(group A), diabetic rats (group C) and diabetic rats fed diet containing 
P.anisum (group D). 
While the plasma glucose concentration of diabetic rats fed diet only is 
significantly higher than normal rats fed diet only (group A).The plasma glucose 
concentration of diabetic rats fed diet containing P.anisum (group D) was 
significantly lower than diabetic rats fed diet only (group C), but significantly 
higher than normal rats fed diet only (group A) and normal rats fed diet containing 
P.anisum (Group B). 
Three hours after feeding, the glucose level of normal fed diet and P.anisum 
(Group B) was significantly higher than normal rats feed diet only (group A) 
(88.7vs84.8) .While plasma glucose concentration of diabetic rats fed diet only 
(group C) was significantly higher than normal rats (group A and Group B) and 
diabetic rats fed P.anisum (group D), when examined three hours after feeding.     
 
 3. 3 The effect of feeding P.anisum on plasma total protein and plasma 
albumin of normal and diabetic rats 
When P.anisum fed to normal and diabetic rats, it was noticed, that the feeding of 
P.anisum had no effect on plasma total protein concentration as shown in table 
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3The level of plasma albumin of normal rats (group A), and normal rats fed diet 
containing P.anisum(Group B) and diabetic rats fed diet only (group C) were not 
significantly different but the feeding of P.anisum significantly decreased the 
albumin concentration of diabetic rats(group D) when compared with normal rats 
fed   P.anisum (Group B)  (3.71vs4.31) . 
 
3.4 The effect of feeding P.anisum on GOT, GPT and alkaline phosphatase 
enzymes of normal and diabetic rats 
The feeding of P.anisum had no significant effect on plasma concentration of 
GOT, GPT and alkaline phosphatase enzymes of normal and diabetic rats 
(p>0.05). 
However, the feeding of P.anisum to normal rats (Group B) increased numerically 
the plasma concentration of GOT when compared with normal rats (Group A) 
(7.33 vs 5.66) and increased numerically the plasma concentration of diabetic rats 
(Group D) when compared with normal rats (Group A) (7.33 vs 5.66) and diabetic 
rats   (Group C) (7.33 vs 6.16). 
The feeding of P.anisum decreased numerically the plasma GPT concentration of 
normal rats  (Group B) when compared with normal rats fed diet only (Group A) 
(4.66 vs 6.66), but feeding P.anisum increased slightly the concentration of GPT 
plasma concentration of diabetic rats (Group D)  when compared with diabetic 
rats fed diet only (Group C) (4.66 vs 4.16) . 
 The Alkaline phosphatase plasma concentration was almost the same in all 
experimental groups (p=0.106) as shown in table 4 
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Figure 5: Level of the glucose at Zero and 48 hours after Streptozotocin injection 
Where: 
A Normal group. 
B Normal group. 
C Injected with Streptozotocin. 
D Injected with Streptozotocin. 
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Table (2): The effect of feeding P. anisum on plasma glucose concentration of 
normal and diabetic rats 
 
Treatment Test 
A B C D 
SD Prob 
0 h 77.83a 71.80 a 220.5 b 193.93 c 103.36 0.00 
1 h 155.8 a 15308 a 335.8 b 315.3 c 101.36 0.00 
2 h 101.0 a 96.67 b 333.7 c 284.3 d  99.36 0.01 
3 h 84.83 a 88.67 b 330.7 c 261.0 d 105.36 0.09 
 
Mean values have different superscript letters within each raw differ significantly 
at (P≤0.05) 
 
Table (3) the effect of feeding P. anisum on normal and diabetic rats plasma total 
protein and albumin 
Treatment Test 
A B C D 
SD Prob 
Total Protein 
(g/dl) 
7.53 a 7.25 a  7.2 a 7.32 a 0.14 0.174 
Albumin(g/dl) 4.15ab 4.31a 4.00ab 3.71b 0.25 0.009 
Mean values have different superscript letters within each raw differ significantly 
at (P≤0.05) 
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3. 5 The effect of feeding P.anisum on normal and diabetic rats plasma 
concentration of cholesterol, triglyceride and bilirubin 
The feeding of P.anisum did not affect significantly the plasma cholesterol of 
normal rats(Group B)when compared with normal rats fed diet only (Group A) 
(185.2 vs183.5) nor plasma cholesterol of diabetic rats (Group D)when compared 
with diabetic rats fed diet only  (Group C) (198.0 vs207.5) . 
It was noticed the plasma cholesterol concentration of diabetic rats (Group C and 
Group D) was numerically higher than normal rats (Group A and Group B) (207.5 
- 198.0 vs183.5 - 185.2)  
Also the feeding of P.anisum did not affect significantly the concentration of 
plasma triglyceride of normal rats(Group B)when compared with normal rats fed 
diet only (Group A) (182.8 vs 180.5),nor plasma triglyceride of diabetic rats 
(Group D)when compared with diabetic fed diet only  (Group C) (172.8 
vs166.8).However, the plasma triglyceride concentration of diabetic rats (group C) 
was significantly lower than normal rats fed diet alone (Group A) and normal rats 
fed P.anisum (Group B). 
The plasma bilirubin concentration was not significantly affected by feeding 
P.anisum in normal rats (Group A vs. Group B) (0.866 vs. 0.780) nor in diabetic 
rats (Group C vs. Group D) (0.683 vs. 0.750). 
The plasma bilirubin concentration of diabetic rats (Group C) was numerically 
lower than that of normal rats fed diet alone (Group A) (0.683 vs. 0.866) as shown 
in table 5. 
 3. 6 The effect of feeding P.anisum on normal and diabetic rat's plasma urea 
and creatinine concentrations 
The feeding of P.anisum did not affect significantly the plasma urea concentration 
of normal rats (Group A vs Group B) nor diabetic rats (Group C vs Group D), but 
numerically decreased the plasma urea of diabetic rats (27.83 vs 34) when 
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compared with diabetic rats. 
However, the plasma urea concentration of diabetic rats(Group C)and diabetic rats 
fed P.anisum (Group D)was significantly higher than normal rats (Group A) and 
normal rats fed P.anisum(Group B) as shown in table 5. 
The feeding of P.anisum did not affect significantly the plasma creatinine 
concentration when fed to normal rats (Group A vs Group B) nor diabetic rats 
(Group C vs Group D), but lowered numerically the plasma creatnine 
concentration of diabetic rats   (Group C vs Group D) (0.816 vs 0.700) ) as shown 
in table 6. 
3. 7 The effect of feeding P.anisum on normal and diabetic rats plasma 
sodium (Na+) and potassium (K+ ) concentrations: 
The plasma sodium concentration was not significantly affected when P.anisum 
was fed to normal rats (Group A vs Group B) (137.2 vs 143.2) nor when fed to 
diabetic rats (Group C vs Group D) (140.2 vs 138.8) 
The feeding of P.anisum increased numerically the plasma potassium 
concentration of normal rats (Group A vs Group B) (3.75vs 3.96) but increased 
significantly the plasma potassium concentration of diabetic rats (Group C vs 
Group D) (3.7 vs 4.10) as shown in table 7. 
3.8 The effect of feeding P.anisum on body weight of normal and diabetic 
rats: 
The feeding of P.anisum decreased significantly the body weight of normal rats 
(Group B vs. Group A) and diabetic rats (Group D vs. Group C) as shown in table 
8. The body weight of diabetic rats whether fed diet only (group C) or fed diet 
containing P.anisum  was significantly lower than the body weight of normal rats 
(group A),While the body weight of diabetic rats fed P.anisum was significantly 
lower than normal rats fed P.anisum (group B) and diabetic rats fed diet only 
(group C ). 
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Table (4) the effect of feeding P.anisum on GOT, GPT and ALK phosphatase 
plasma concentration of diabetic and normal rat’s enzymes 
Treatment Test 
A B C D 
SD Prob 
GOT (U/I) 5.66a 7.33a 6.16a 7.33a 084 0.357 
GPT(U/I) 6.66a 4.66b 4.16b 4.66b 1.10 0.053 
ALK 
phosphatase 
(U/I) 
170.5a 167.2a 169.0a 173.5a 2.67 0.106 
 
Mean values have different superscript letters within each raw differ significantly 
at (P≤0.05) 
Table (5) the effect of feeding P.anisum on normal and diabetic rat's plasma 
cholesterol, triglyceride and bilirubin concentrations 
Treatment Test 
A B C D 
SD Prob 
Cholesterol 
(mg/l) 
183.5b 185.2b 207.5a 198.0a 11.00 0.00 
Triglyceride 
(mg/dl) 
180.5a 182.8a 166.8b 172.8ab 7.32 0.00 
Bilirubin (mg/l)   
 
0.866a 0.780a 0.683a 0.750a 0.07 0.246 
 
Mean values have different superscript letters within each raw differ significantly 
at (P≤0.05 ) 
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Table (6) the effect of feeding P.anisum on normal and diabetic rat's plasma urea 
and creatinine concentrations 
 
Treatment Test 
A B C D 
SD Prob 
Urea (mg/dl) 20.17b 20.33b 34.00a 27.83a 6.65 0.000 
Creatinin 
(mg/dl) 
0.633a 0.650a 0.816a 0.700a 0.08 0.330 
Mean values have different superscript letters within each raw differ significantly 
at (P≤0.05) 
 
Table (7) the effect of feeding P.anisum on normal and diabetic rats’ plasma 
sodium (Na+) and potassium (K+) concentration. 
 
Treatment Test 
A B C D 
SD Prob 
Sodium (Na+) 
(%) 
137.2 a 
 
143.3 a 
 
140.2 a 
 
138.8a 2.61 0.139 
Potassium (K+)  
(%) 
3.75 b 
 
3.96 ab 
 
3.70 b 
 
4.10 a 
 
0.18 0.018 
 
Mean values have different superscript letters within each raw differ significantly 
at (P≤0.05) 
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Table (8) the effect of feeding P.anisum on body weights of normal and diabetic 
rats  
Treatment Test 
A B C D 
SD Prob 
Body Weight (g) 125.9 a 
 
95.27 b
 
98.40 b 
 
92.77c 18.194 0.00 
 
Mean values have different superscript letters within each raw differ significantly 
at (P≤0.05) 
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Chapter Four 
4.                                      Discussion 
 
Many experiments and clinical trials were made to detect the hypoglycemic and 
antidiabetic effects of some medicinal plants used for treatment of diabetes 
mellitus such as Zizphus Lotus(Glomitza et al.,1994), Citrullus colocyrithis 
(Wasfi,1994), Jumibers communis, and cinnamon.P.anisum is medicinal plant , 
which has antimicrobial activity against bacteria  and fungi, anti-oxidant activity 
and increase glucose absorption activity (Kreydiyyeh et al.,2003). 
The current study was carried out to investigate the antidiabetic effect of 
P.anisum.The effects of feeding P.anisum on normal rats and streptozotocin 
induced diabetic rats were examined .Glucose tolerance test was performed and 
plasma total protein ,albumin ,cholesterol ,triglyceride ,bilrubin ,Na+, K+, 
enzymes and body weight were monitored. 
In this experiment, diabetes mellitus was induced in rats by injection of 
streptozotocin and the glucose tolerance test confirmed ,the injection of 
streptozotocin could induced diabetes mellitus as also shown by previous 
experiments. The diabetogenic effect of this antibiotic is mediated by B-cell 
destruction, which result in development of an insulin dependent syndrome. This 
condition is most commonly associated with hypoinsulinaemia and it may occur 
as primary entity or may be associated with acute pancreatic necrosis (Greene and 
Latimar,1983).The fasting insulin decreased to about one third and fasting 
glucagons increases  three fold (Admdal et al.,1986).This result in raised glucose 
concentration in experimentally induced diabetic rats (Greene and 
lattimar,1983).Glucose tolerance test carried out in this experiment showed ,the 
feeding of P.anisum to diabetic rats lowered significantly the plasma glucose level 
of diabetic rats (Group D vs Group C) when measured at 0,1,2,3 h after fasting 
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.This indicates P.anisum feeding has significant effect on concentration of plasma 
glucose in diabetic rats. However, the feeding of P.anisum did not lower the 
plasma glucose level to normal concentration when diabetic rats fed P.anisum 
(Group D) were compared  with normal rats whether fed P.anisum (Group B) or 
not (Group A) . 
In this study, it was noticed , the feeding of P.anisum to normal rats (Group B vs 
Group A) lowered numerically the plasma glucose level at 0h, and had no effect at 
1h and  increased the level  significantly at 3h but the difference was small . 
It seems, the P.anisum feeding has more pronounce effect on plasma glucose 
concentration in diabetic rats. This agrees with previous studies which showed 
medicinal plants, Zizphus lotus (Glombitza et al., 1994), and Jumibers commuins 
berries had antidiabetic effect and lowered the blood glucose level in induced 
diabetic rabbits and rats. Also it was found that, cinnamon reduced the mean 
fasting serum glucose (18-29%) in people with type 2 diabetes ( Khan et al., 
2003).Zizyphus lotus caused significant reduction in fasting serum glucose and 
improved glucose utilization in alloxan diabetic rabbits (Glombitaz et al., 1994) . 
The hypoglycemic activity of J.communis berries is due to an increases 
consumption of peripheral glucose and or increased insulin secretion. Thus, it can 
be concluded P.anisum has some antidiabetic effect. Further work is needed to 
investigate the mechanism of action and to identify the active ingredients of 
P.anisum 
The feeding of P.anisum had no effect on plasma total protein and albumin 
concentration in normal or diabetic rats in this study .This revealed the feeding of 
P.anisum has no deleterious effect on liver or kidney, since it was reported that 
drastic alteration in plasma proteins values may be observed in association with 
both kidney and liver diseases (Coles, 1986)  
However, the albumin concentration in diabetic rats fed P.anisum (Group D) and 
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plasma albumin in diabetic rats fed diet only(Group C ) was significantly low 
when compared with normal rats (Group A). This hypoalbuminia may be 
attributed to diabetes, as it is known hypoalbuminia develop as result of excessive 
breakdown which occurs in prolonged fever, and uncontrolled diabetes mellitus 
(Coles,1986). 
The feeding P.anisum had no significant effect on plasma GOT,GPT and  alkaline 
phosphatase in both normal and diabetic rats in this experiment ,but the feeding 
increased numerically the plasma GOT level in both normal and diabetic rats .This 
numerical increase in GOT might indicate slight pathological changes in the liver 
as GOT increased in serum when cellular degeneration or destruction in the liver 
occurs ( Coles,1986 ).  
Also in this experiment there was no significant differences in plasma GOT and 
GPT between normal and diabetic rats this disagree with Awadallah and El-
Dessouky(1977) who reported significant increase in GOT and GPT when normal 
rats were compared with diabetic rats .Also disagree with Mannipieri et al 
.(2005)who reported that higher GOT (ALT) was significantly associated with 
both impaired glucose tolerance and diabetes. 
This study reveal significant changes in plasma alkaline phosphatase in diabetic 
rats when compared with normal rats .However, Mannipieri et al. (2005) reported 
significant association between higher alkaline phosphatase and diabetics. 
In this experiment, the feeding of P.anisum did not affect significantly the plasma 
cholesterol level in normal or diabetic rats .It was also observed, the cholesterol 
level of diabetic rats (Group C and D) was significantly higher than that of normal 
rats (Group A and B) .Blood cholesterol levels invariably increased in diabetic 
animals and high total cholesterol levels were observed in dogs with leptospirosis 
,diabetes mellitus or nephritis (Coles , 1986). 
It was also noticed in the current experiment, the level of plasma triglyceride was 
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not affected by feeding P.anisum to normal or diabetic rats but triglyceride level 
in the diabetic rats fed diet only (Group C) was significantly lower than normal 
rats whether fed diet only (Group A) or diet with P.anisum (Group B) .This 
disagree with findings of Khan et al. (2003) who reported high triglyceride level 
which was reduced by consumption of cinnamon by human patient with type 1 
diabetes. 
The plasma bilrubin level was not significantly different in normal and diabetic 
rats ,however the bilrubin level in diabetic rats was numerically lower than normal 
and diabetic rats fed P.anisum .This reduction in bilrubin agree with that of Stone 
et al .(1997) who reported significant increase  bile acid excretion and bile flow in 
streptozotocin induced diabetic rats and decrease in plasma bilrubin concentration. 
This explains by the fact that, the bilrubin increase is due to decreased removal of 
bilrubin by hepatocellular transport (Coles, 1986). 
The plasma urea concentration in normal and diabetic rats was not affected 
significantly by P.anisum feeding .This indicates P.anisum probably has no 
deleterious effect on the liver or the kidney of normal and diabetic rats. 
Elevation of plasma urea in diabetic rats was observed in this investigation. This 
agree with that of Almdal et al .(1986) who found in streptozotocin induced 
diabetic rats ,urea nitrogen synthesis capacity was doubled . They suggested the 
increase of urea synthesis to be due to enzyme induction by glucagon enzyme 
which increases in diabetic rats.Cole (1986) stated that ureamia is frequently seen 
with diabetes mellitus, although it is not a consistent finding. 
The plasma creatinine level was not affected significantly in normal rats by 
P.anisum feeding but the feeding decreased numerically the creatinine 
concentration in diabetic rats (Group D and Group C). 
The level of plasma creatinine in diabetic rats was not significantly different from 
that of normal rats but it was numerically higher as the rate of secretion of 
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creatinine is influenced by GFR and abnormality that decreases GFR will result in 
an increase in the concentration of serum creatinine (Coles, 1986).It seems, 
induced diabetes influenced slightly the GFR in rats and thus increases 
numerically the creatinine level in diabetic rats .Also, it seems , P.anisum feeding 
relieved to some extend the diabetogenic  effect and lowered numerically the level 
of plasma creatinine of diabetic rats (Group D vs  Group C). 
 
The concentrations of Na+ in plasma in normal and diabetic rats were not 
significantly different. This showed the feeding of P.anisum has no effect on 
plasma Na+ concentration in normal and diabetic rats and also diabetes had no 
effect on plasma Na+ concentration in diabetic rats .Coles (1986) stated that , 
there may be occasional hyponatremia and sodium may be lost as consequence of 
impaired kidney reabsorption  associated with osmatic diuresis.It seems P.anisum 
or diabetes had no deleterious effect that impaired kidney tubular reabsorption. 
The P.anisum feeding in this study did not increased significantly the level of K+ 
in normal rats , but increased significantly  K+ in diabetic rats (Group D vs  Group 
C).This experiment also showed there was significant increase in plasma K+ 
concentration in diabetic rats fed P.anisum when compared with normal rats fed 
diet only .Hyperkalemia may develop when a patient with renal disease become 
oliguria or anuric ,as K+ is retained (Coles,1986).The increase plasma K+ 
concentration in diabetic rats fed P.anisum might be a result of combined effect of 
P.anisum feeding and diabetes on the kidney which result in some renal damage 
or other cause. 
The P.anisum feeding in this study decreased significantly the body weight of 
normal rats (125.1vs 95.27) and diabetic rats (98.4 vs 92.8).This may be attributed 
to replacement of 30% of the diet by P.anisum seeds which may have less 
nutritive value than the diet. Also, it was observed in this study, the body weight 
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of diabetic rats was significantly lowered than the body weight of normal rats 
(98.4 vs125.9).The reduction in the body weight of diabetic rats confirms the 
previous work of Greene and lattimer (1983) which showed experimental diabetes 
significantly lowered the final body weight by about 48%.Weight loss is clinical 
sign associated with diabetes (Coles, 1986). 
It can be concluded, P.anisum is promising antidiabetic agent and could be used to 
lower hyperglycemia in diabetic patient.        
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Conclusions and Recommendations 
Conclusions: 
From the observation and results of this investigation, it can be concluded that: 
1. P.anisum seeds decreased significantly plasma glucose level in streptozotocin 
induced diabetic rats. 
2. Therefore, P.anisum could be considered a promising antidiabetic agent to 
reduce blood glucose in diabetic patients. 
3.  Inclusion of P.anisum in rat diet decreased significantly the body weight this 
revealed P.anisum do not contribute to caloric intake. Hence P.anisum could 
be included in the diet or regularly intake by diabetic patients or those have 
elevated blood glucose. 
4. P.anisum is safe as it showed no or little signs of toxicity 
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Recommendations: 
Since P.anisum is promising antidiabetic agent it is recommended that: 
1. Further research should be carried out to determine the mechanism of action of 
P.anisum on blood glucose. 
2. The active ingredient in P.anisum should be identified and purified. 
3. To exclude the possibility of human poisoning, further research should be 
carried out to examine the safety and toxicity of P.anisum and also to 
determine the proper dosage and potential interactions with other medicinal 
plant and synthetic drugs. 
4. If P.anisum proved safe ,limited treatment trial to treat both type 1 and type 2 
diabetic human patients is recommended 
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